AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34348352
Drug: Hydrocortisone acetate
RxNorm normalized name: Hydrocortisone Acetate
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone acetate 1% cream (HC)
Trial: 34348352
Drug: Methylprednisolone aceponate
RxNorm normalized name: Methylprednisolone aceponate
DrugBank: Methylprednisolone aceponate (DB14643)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone aceponate 0.1% cream (MPA)
Trial: 34348352
Drug: Active agent-free
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active agent-free base cream (Dermatop® Basiscreme)
Trial: 33509248
Drug: Regular knee
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular knee arthroscopic therapy
Trial: 35994013
Drug: Norepinephrine 0.05–0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine 0.05–0.2 µg/kg/min
Trial: 34323922
Drug: Chemoradiation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiation and metformin
Trial: 34568637
Drug: Quitline treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quitline treatment as usual (TAU)
Trial: 33271092
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of adjuvant chemotherapy (CAPOX or FOLFOX)
Trial: 33271092
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months of adjuvant chemotherapy (CAPOX or FOLFOX)
Trial: 32376477
Drug: Preoperative resistance
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative resistance training (RT), twice a week for 10 weeks prior to THA
Trial: 36294155
Drug: Krill oil
RxNorm normalized name: Krill oil
DrugBank: Krill oil (DB16615)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krill oil (3 g/daily)
Trial: 36294155
Drug: Mineral oil
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineral oil (3 g/daily)
Trial: 34674300
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (ST), 2 weeks of unloading in a plaster cast followed by 4 weeks of weightbearing in an orthosis
Trial: 32570775
Drug: Flavonoid-rich orange
RxNorm normalized name: Orange
DrugBank: Orange (DB10549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavonoid-rich orange juice (FR), 380 mL daily, 600 ± 5.4 mg flavonoids
Trial: 32570775
Drug: Flavonoid-low orange
RxNorm normalized name: Orange
DrugBank: Orange (DB10549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavonoid-low orange cordial (FL), 380 mL daily, 108 ± 2.6 mg flavonoids
Trial: 33303444
Drug: Goal-directed perfusion
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed perfusion (GDP) strategy during cardiopulmonary bypass (CPB) aimed to maintain DO2i at ≥360 mL/min/m2
Trial: 32732515
Drug: Sacubitril/valsartan (Sal/Val)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan (Sal/Val) treatment
Trial: 32732515
Drug: Enalapril treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril treatment (Control)
Trial: 36099671
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (CTX)
Trial: 35380645
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) glucocorticoid injection (triamcinolone acetonide, 40 mg)
Trial: 35380645
Drug: Intra-articular (IA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular (IA) glucocorticoid injection (triamcinolone acetonide, 40 mg)
Trial: 33122571
Drug: Dexmedetomidine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine with total intravenous anaesthesia (DEX‐TIVA)
Trial: 32465270
Drug: <500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: <500 mg MMF/day
Trial: 32465270
Drug: >2000 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: >2000 mg MMF/day
Trial: 32465270
Drug: All MMF
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All MMF dosing groups
Trial: 32462307
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy for anxiety in children with ADHD
Trial: 34352138
Drug: Zuranolone 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zuranolone 45 mg
Trial: 33909356
Drug: Fluoxetine hydrochloride
RxNorm normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine hydrochloride capsule (20 mg once a day)
Trial: 36476479
Drug: csDMARDs plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: csDMARDs plus denosumab (60-mg subcutaneous injection once every 6 months for 12 months)
Trial: 36476479
Drug: csDMARD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: csDMARD therapy alone
Trial: 33289818
Drug: early high‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: early high‐dose recombinant human erythropoietin (rhEpo)
Trial: 32777456
Drug: Palliative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative chemotherapy educational tool with optional life expectancy information
Trial: 32277868
Drug: Switch from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch from protease inhibitors to rilpivirine (RPV)
Trial: 32277868
Drug: Continue ritonavir-boosted
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Continue ritonavir-boosted protease inhibitors (control group)
Trial: 36476171
Drug: Remimazolam 5
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam 5 mg intravenously
Trial: 36476171
Drug: Dexmedetomidine 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.6 µg/kg intravenously
Trial: 36476171
Drug: Midazolam 0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.025 mg/kg intravenously
Trial: 32618713
Drug: Antenatal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antenatal administration of uterotonics
Trial: 34074611
Drug: Symptom-titrated, algorithm-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom-titrated, algorithm-based longitudinal ECT (STABLE) plus pharmacotherapy (venlafaxine and lithium)
Trial: 34074611
Drug: Pharmacotherapy-only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy-only
Trial: 35840611
Drug: Probiotics, daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics, daily doses, duration of 28 days
Trial: 35840611
Drug: Placebo, daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, daily doses, duration of 28 days
Trial: 32043304
Drug: Enteral hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral hydration (via NGT bolus, NGT continuous, both, or oral)
Trial: 32043304
Drug: Intravenous fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluids (IV)
Trial: 32043304
Drug: Mix of
RxNorm normalized name: PHLEUM PRATENSE POLLEN 40000 [BAU] in 1 mL / DACTYLIS GLOMERATA POLLEN 20000 [BAU] in 1 mL / POA PRATENSIS POLLEN 20000 [BAU] in 1 mL / AGROSTIS GIGANTEA POLLEN 20000 [BAU] in 1 mL SUBCUTANEOUS INJECTION, SOLUTION [MIDWEST MIX OF STANDARDIZED GRASS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mix of NGT and oral hydration
Trial: 33268143
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplement (ONS) containing beta‐hydroxy‐beta‐methylbutyrate (HMB) with dietary counseling, two servings/day for 180 days.
Trial: 33268143
Drug: Placebo supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplement with dietary counseling, two servings/day for 180 days.
Trial: 33399351
Drug: Androgen receptor
RxNorm normalized name: Androgen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen receptor (AR) expression in UC/DEAC
Trial: 33399351
Drug: Androgen receptor
RxNorm normalized name: Androgen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen receptor (AR) expression in FIGO 3 endometrioid carcinoma
Trial: 33399351
Drug: Androgen receptor
RxNorm normalized name: Androgen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen receptor (AR) expression in serous carcinoma
Trial: 33399351
Drug: Androgen receptor
RxNorm normalized name: Androgen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen receptor (AR) expression in carcinosarcoma
Trial: 33399351
Drug: Androgen receptor
RxNorm normalized name: Androgen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen receptor (AR) expression in clear cell carcinoma
Trial: 33399351
Drug: Association of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Association of AR expression with hormone receptors in UC/DEAC
Trial: 33399351
Drug: Potential role
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potential role of androgen inhibitors in management of UC/DEAC
Trial: 35209785
Drug: Cognitive Behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavior Therapy (CBT), n=84
Trial: 33131909
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical therapy, diet and exercise
Trial: 33559245
Drug: Magnesium (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium (200 mg) combined with 2 ml bupivacaine and 1 ml (40 mg) methylprednisolone
Trial: 33559245
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (2 ml bupivacaine, 1 ml (40 mg) methylprednisolone and 1 ml saline (0.9%))
Trial: 33369824
Drug: Analgesic treatment
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic treatment and MET (Medical Expulsive Therapy)
Trial: 34297066
Drug: Adipose tissue-derived
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adipose tissue-derived stromal vascular fraction (AD-SVF) injection
Trial: 34682824
Drug: Hyaluronic acid/trehalose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid/trehalose ophthalmic solution (Thealoz® Duo) three times/day in the preoperative week and for 5 postoperative weeks (Group A)
Trial: 34682824
Drug: Hyaluronic acid/trehalose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid/trehalose ophthalmic solution (Thealoz® Duo) for only 5 postoperative weeks (Group B)
Trial: 36065580
Drug: Cognitive Remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Remediation Therapy (CRT) added to IPS
Trial: 32827344
Drug: Automated oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated oxygen administration using the FreeO2 device
Trial: 32827344
Drug: Conventional manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional manual oxygen administration
Trial: 32047601
Drug: Multiple visit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple visit endodontic treatment with triple antibiotic paste interappointment dressing
Trial: 32047601
Drug: Single visit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single visit endodontic treatment without interappointment dressing
Trial: 34409931
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) alone
Trial: 33395182
Drug: Low-volume plyometric
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume plyometric training (40-60 ground contacts per session, twice weekly) in HV-1 group
Trial: 33395182
Drug: Low-volume plyometric
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume plyometric training (40-60 ground contacts per session, twice weekly) in VH-2 group
Trial: 36184472
Drug: Low tidal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tidal volume (LTV), pressure controlled ventilation (PCV), respiratory rate (RR) 20‐to‐30/min, peak inspiratory pressure adjusted to keep tidal volume (Vt) 2 mL/kg
Trial: 36344005
Drug: Liberal oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal oxygen strategy (12-15 L O2/min or FiO2=0.6-1.0)
Trial: 34226449
Drug: Econazole Nitrate
RxNorm normalized name: Econazole Nitrate
DrugBank: Econazole (DB01127)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Econazole Nitrate 1% + Triamcinolone Acetonide 0.1% cream
Trial: 32956782
Drug: HCQ/AZT combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCQ/AZT combination
Trial: 32572664
Drug: HIPEC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIPEC plus adjuvant chemotherapy
Trial: 32464799
Drug: Extracorporeal photopheresis
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal photopheresis plus standard immunosuppressive therapy (ECP)
Trial: 33825723
Drug: Pletax® (cilostazol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pletax® (cilostazol) 100 mg twice daily
Trial: 33825723
Drug: Trental® (pentoxifylline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trental® (pentoxifylline) 400 mg three times daily
Trial: 34855311
Drug: H. psudoplicatum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. psudoplicatum supplementation (250 mg/day for 6 weeks)
Trial: 34855311
Drug: Placebo (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (250 mg/day for 6 weeks)
Trial: 35172981
Drug: CALM (Managing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CALM (Managing Cancer and Living Meaningfully) therapy
Trial: 35472303
Drug: Screening for
RxNorm normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening for AF using a 2-week single-lead electrocardiographic patch monitor
Trial: 34097044
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of BNT162b2 vaccine
Trial: 34543417
Drug: Ledipasvir/Sofosbuvir treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir/Sofosbuvir treatment (12-week course)
Trial: 34543417
Drug: Low adherence
RxNorm normalized name: dressing,low adherence and wound contact materials
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low adherence (taking <90% of doses)
Trial: 34543417
Drug: High adherence
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High adherence (taking ≥90% of doses)
Trial: 34292792
Drug: T300 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T300 + D (tremelimumab 300 mg plus durvalumab 1,500 mg followed by durvalumab 1,500 mg once every 4 weeks)
Trial: 34292792
Drug: Durvalumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab monotherapy (1,500 mg once every 4 weeks)
Trial: 34292792
Drug: Tremelimumab monotherapy
RxNorm normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab monotherapy (750 mg once every 4 weeks for seven doses, then once every 12 weeks)
Trial: 34292792
Drug: T75 +
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: T75 + D (tremelimumab 75 mg once every 4 weeks plus durvalumab 1,500 mg once every 4 weeks for four doses, then durvalumab 1,500 mg once every 4 weeks)
Trial: 35692047
Drug: Partial brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial brain radiotherapy (RT) followed by procarbazine, lomustine, and vincristine (PCV) chemotherapy (RT-PCV)
Trial: 34210341
Drug: Metacognitive Remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metacognitive Remediation Therapy (MCR)
Trial: 35025539
Drug: Supportive-Expressive Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive-Expressive Therapy (SET)
Trial: 34404446
Drug: Combined physical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined physical and internet‐delivered psychological intervention (psychologically informed physical treatments)
Trial: 34273498
Drug: Add-on dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on dry powder inhalation (DPI) of combined anti-TB therapy (isoniazid 5 mg, rifampicin 2 mg, pyrazinamide 16 mg, levofloxacin 2 mg)
Trial: 34273498
Drug: Add-on dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on dry powder inhalation (DPI) of combined anti-TB therapy
Trial: 32701597
Drug: Sertraline (SSRI)
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline (SSRI)
Trial: 35758850
Drug: SpikoGen® vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SpikoGen® vaccine
Trial: 35574009
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart injected with a needle-free syringe into the abdomen
Trial: 35574009
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart injected with a needle-free syringe into the upper arm
Trial: 35574009
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart injected with a needle-free syringe into the thigh
Trial: 34082633
Drug: Demographic factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demographic factors (drug-use-related disorders)
Trial: 36434514
Drug: ZYN002 (cannabidiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZYN002 (cannabidiol transdermal gel) 250 mg or 500 mg daily for 12 weeks
Trial: 35050705
Drug: App-based visual-acoustic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: App-based visual-acoustic biofeedback using Speech Therapist's App for /r/ Treatment
Trial: 35050705
Drug: Nonbiofeedback treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonbiofeedback treatment using Speech Therapist's App for /r/ Treatment
Trial: 38630471
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of treatment success rates
Trial: 33191408
Drug: Belotecan (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belotecan (0.5 mg/m2)
Trial: 33191408
Drug: Topotecan (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan (1.5 mg/m2)
Trial: 33203854
Drug: Lapatinib (L;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (L; N = 36)
Trial: 32803294
Drug: N-acetylcysteine inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine inhalation therapy (2400 mg daily for 8 weeks)
Trial: 34325680
Drug: Severe anaemia
RxNorm normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe anaemia (Hb 4-6 g/dL and no severity features), no transfusion during initial admission
Trial: 34325680
Drug: Missing ≥1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Missing ≥1 trial medication dose
Trial: 35311593
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg shrimp oil once per day for eight weeks
Trial: 35598698
Drug: Time to
RxNorm normalized name: Overtime Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time to 50% daily calorie intake
Trial: 32919068
Drug: High-dose eplerenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose eplerenone (100-200 mg)
Trial: 32664953
Drug: Restriction of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restriction of enteral feed volume to 120 ml/kg/day for 12 hours
Trial: 35918311
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g of dried psilocybin mushrooms
Trial: 35998623
Drug: SOBERANA 02
RxNorm normalized name: Soberana 01
DrugBank: FINLAY-FR-1 (DB16524)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOBERANA 02 (two doses) + SOBERANA Plus (third dose)
Trial: 34310011
Drug: ORMD-0801 (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORMD-0801 (16 or 24 mg, once daily at bedtime for 28 days)
Trial: 34189703
Drug: GSK2586881 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2586881 0.8 mg/kg
Trial: 34783100
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) prescribed if blood eosinophils ≥3%
Trial: 34783100
Drug: Targeted antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted antibiotics for airway bacterial infection
Trial: 32929822
Drug: Pharmacist-led, patient-oriented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led, patient-oriented education and medication management intervention
Trial: 36509053
Drug: Azithromycin (single-dose)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin (single-dose)